TSE:DN

Delta 9 Cannabis Competitors

C$0.57
0.00 (0.00 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.56
Now: C$0.57
C$0.57
50-Day Range
C$0.48
MA: C$0.55
C$0.60
52-Week Range
C$0.43
Now: C$0.57
C$0.75
Volume64,908 shs
Average Volume248,604 shs
Market CapitalizationC$58.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Delta 9 Cannabis (TSE:DN) Vs. WLLW, LABS, KHRN, META, NRTH, and CSI

Should you be buying DN stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to Delta 9 Cannabis, including Willow Biosciences Inc. (WLLW.TO) (WLLW), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Meta Growth (META), 48North Cannabis (NRTH), and (CSI) (CSI).

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Willow Biosciences Inc. (WLLW.TO) and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Willow Biosciences Inc. (WLLW.TO)0000N/A
Delta 9 Cannabis00014.00

Willow Biosciences Inc. (WLLW.TO) currently has a consensus target price of C$2.25, indicating a potential upside of 78.57%. Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Delta 9 Cannabis' higher probable upside, analysts plainly believe Delta 9 Cannabis is more favorable than Willow Biosciences Inc. (WLLW.TO).

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Valuation & Earnings

This table compares Willow Biosciences Inc. (WLLW.TO) and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)C$10,000.0015,531.77C$-51,032,952.00C($0.41)-3.04
Delta 9 CannabisC$52.05 million1.12C$-7,346,808.00C($0.07)-7.92

Delta 9 Cannabis has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Willow Biosciences Inc. (WLLW.TO), indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Willow Biosciences Inc. (WLLW.TO) on 5 of the 7 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for MediPharm Labs and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
Delta 9 Cannabis00014.00

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given MediPharm Labs' higher probable upside, research analysts plainly believe MediPharm Labs is more favorable than Delta 9 Cannabis.

Profitability

This table compares MediPharm Labs and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Valuation & Earnings

This table compares MediPharm Labs and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98
Delta 9 CannabisC$52.05 million1.12C$-7,346,808.00C($0.07)-7.92

Delta 9 Cannabis has higher revenue and earnings than MediPharm Labs. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Khiron Life Sciences (CVE:KHRN) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Khiron Life Sciences and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Valuation & Earnings

This table compares Khiron Life Sciences and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesC$8.01 million8.81C$-39,493,921.00C($0.26)-1.79
Delta 9 CannabisC$52.05 million1.12C$-7,346,808.00C($0.07)-7.92

Delta 9 Cannabis has higher revenue and earnings than Khiron Life Sciences. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Khiron Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Khiron Life Sciences and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences0000N/A
Delta 9 Cannabis00014.00

Khiron Life Sciences currently has a consensus target price of C$1.20, indicating a potential upside of 155.32%. Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Khiron Life Sciences' higher probable upside, research analysts plainly believe Khiron Life Sciences is more favorable than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats Khiron Life Sciences on 4 of the 7 factors compared between the two stocks.

Meta Growth (CVE:META) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Meta Growth and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Valuation and Earnings

This table compares Meta Growth and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
Delta 9 CannabisC$52.05 million1.12C$-7,346,808.00C($0.07)-7.92

Delta 9 Cannabis has lower revenue, but higher earnings than Meta Growth. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Meta Growth and Delta 9 Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
Delta 9 Cannabis00014.00

Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than Meta Growth.

Summary

Delta 9 Cannabis beats Meta Growth on 5 of the 7 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares 48North Cannabis and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
48North CannabisN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for 48North Cannabis and Delta 9 Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
48North Cannabis0000N/A
Delta 9 Cannabis00014.00

Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than 48North Cannabis.

Valuation and Earnings

This table compares 48North Cannabis and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
48North CannabisC$17.36 million1.88C$-59,218,395.00C($0.26)-0.55
Delta 9 CannabisC$52.05 million1.12C$-7,346,808.00C($0.07)-7.92

Delta 9 Cannabis has higher revenue and earnings than 48North Cannabis. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats 48North Cannabis on 5 of the 7 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and (CSI) (CNSX:CSI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Delta 9 Cannabis and (CSI)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
(CSI)N/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Delta 9 Cannabis and (CSI), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
(CSI)0000N/A

Delta 9 Cannabis currently has a consensus price target of C$1.10, indicating a potential upside of 92.98%.

Valuation and Earnings

This table compares Delta 9 Cannabis and (CSI)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$52.05 million1.12$-7,346,808.00C($0.07)-7.92
(CSI)N/AN/AN/AN/AN/A

(CSI) has lower revenue, but higher earnings than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats (CSI) on 2 of the 2 factors compared between the two stocks.


Delta 9 Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.26flatC$155.32 millionC$10,000.00-3.04
LABS
MediPharm Labs
1.4$0.47flatC$121.24 millionC$36.01 million-0.98
KHRN
Khiron Life Sciences
0.9$0.47flatC$67.34 millionC$8.01 million-1.79
META
Meta Growth
0.8$0.14flatC$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.15flatC$36.44 millionC$17.36 million-0.55Gap Down
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.